Closing Figures: Pacific Biosciences of California Inc (PACB)’s Negative Finish at 1.02, Down -1.45

Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

After finishing at $1.03 in the prior trading day, Pacific Biosciences of California Inc (NASDAQ: PACB) closed at $1.02, down -1.45%. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 4.18 million shares were traded.

Ratios:

Our goal is to gain a better understanding of PACB by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.87 and its Current Ratio is at 6.68. In the meantime, Its Debt-to-Equity ratio is 7.63 whereas as Long-Term Debt/Eq ratio is at 7.60.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 03 ’25 when HENRY CHRISTIAN O sold 12,497 shares for $1.41 per share. The transaction valued at 17,583 led to the insider holds 2,225,357 shares of the business.

Van Oene Mark sold 6,486 shares of PACB for $9,126 on Mar 03 ’25. The insider now owns 1,497,695 shares after completing the transaction at $1.41 per share. On Mar 03 ’25, another insider, Farmer Michele, who serves as the insider of the company, sold 2,973 shares for $1.41 each. As a result, the insider received 4,183 and left with 184,619 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 2.01 while its Price-to-Book (P/B) ratio in mrq is 3.34.

Stock Price History:

Over the past 52 weeks, PACB has reached a high of $2.72, while it has fallen to a 52-week low of $0.95. The 50-Day Moving Average of the stock is -15.08%, while the 200-Day Moving Average is calculated to be -37.19%.

Shares Statistics:

A total of 300.04M shares are outstanding, with a floating share count of 264.15M. Insiders hold about 11.97% of the company’s shares, while institutions hold 65.80% stake in the company.

Earnings Estimates

The performance of Pacific Biosciences of California Inc (PACB) in the stock market is under the watchful eye of 11.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.13 and low estimates of -$0.17.

Analysts are recommending an EPS of between -$0.59 and -$0.68 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is -$0.51, with 12.0 analysts recommending between -$0.38 and -$0.62.

Revenue Estimates

10 analysts predict $36.35M in revenue for the current quarter. It ranges from a high estimate of $37.3M to a low estimate of $34M. As of the current estimate, Pacific Biosciences of California Inc’s year-ago sales were $36.01MFor the next quarter, 10 analysts are estimating revenue of $39.71M. There is a high estimate of $42M for the next quarter, whereas the lowest estimate is $37.9M.

A total of 11 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $160.2M, while the lowest revenue estimate was $150.28M, resulting in an average revenue estimate of $155.64M. In the same quarter a year ago, actual revenue was $154.01MBased on 13 analysts’ estimates, the company’s revenue will be $186.94M in the next fiscal year. The high estimate is $222.32M and the low estimate is $164.53M.

Most Popular